Coreceptor usage and tropism for MDM.

aTime-point from which the patient env was amplified, in days from onset of symptoms characteristic of PHI.
bVirus susceptibility to neutralization by heterologous sera (see Fig. 1); S, sensitive: R, resistant.
cCoreceptor tropism assessed on NP-2/U87 indicator cells expressing CD4 and one of the putative coreceptors CCR5, CXCR4 and CCR3. Coreceptors supporting viral entry within 1 log10 (or in brackets 2 log10) of the level seen with the preferred coreceptor are listed; R5, CCR5; R3, CCR3; X4, CXR4.
dAssessed by p24 immunostaining four days post-inoculation. The tropism for MDM is scored relative to the virus titre on NP-2/CD4/CCR5 cells; +++ titre on MDM>90% of the titre on NP-2 cells; ++ >10%: + >1%; (+) >0.1%; -, no detectable infection or <0.1% of titre on NP-2 cells.
eThe coreceptor usage of the Envs from acute infection and the first chronic infection time-point has been reported previously [31], [32], as have the data on MDM tropism for MM4′s and MM8′s viruses [50].